Product Pipeline
In March 2000, the Infectious Disease Research Institute (IDRI) received a $15 million grant from the Bill & Melinda Gates Foundation to fund its ongoing effort with Corixa to develop a vaccine to prevent and treat leishmaniasis. In January 2003, we initiated a U.S. Phase I clinical trial to test the safety and tolerability of an investigational vaccine to treat various forms of leishmaniasis.

Related News
01/13/2003 Corixa and IDRI initiate U.S. Phase I trial of leishmaniasis vaccine
03/23/2000 IDRI receives $15 million from Gates Foundation
A business overview as well as information on Corixa's partners, management team, employment opportunities, and company contacts.
Corixa's near-term products and adjuvant for research applications.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.
Company reports, stockholder letter, events calendar, stock quote, analyst list, and materials request.
Current and archived company press releases.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.